Genocea Biosciences, Inc.

Robbins LLP: Genocea Biosciences, Inc. (GNCA) Misled Shareholders According to a Recently Amended Class Action

Robbins LLP announces that shareholders amended their class action complaint filed against Genocea Biosciences, Inc. (NasdaqGM: GNCA). The complaint is brought on behalf of all purchasers of Genocea securities between May 5, 2017 and September 25, 2017, for alleged violations of the Securities Exchange Act of 1934 by Genocea's officers and directors. Genocea, a biopharmaceutical company, develops T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. Genocea's genital herpes immunotherapy product, GEN-003, is the company's lead product candidate.

Genocea Accused of Overstating the Prospects for its Lead Drug Candidate

According to the complaint, on July 24, 2017, Genocea gave a presentation to investors regarding the positive clinical results for the 12-month analysis of the company's Phase 2b trial of GEN-003. Genocea subsequently stated in its public filings that the company had a successful end-of-Phase 2 meeting with the U.S. Food and Drug Administration. However, Genocea did not disclose that the company's finances were insufficient to support Phase 3 trials of GEN-003 and that Genocea had overstated the prospects for GEN-003. On September 25, 2017, Genocea disclosed that it was halting spending and activities on GEN-003, exploring strategic alternatives for the drug, and that it was cutting 40% of its workforce. On this news, Genocea's stock fell $4.08 per share, or 76.5%, to close at $1.25 per share on September 26, 2017.

Genocea Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, or you can complete the form below and we will contact you directly.

Send us a message for more information.

Skip to content